|
Mr. Howard-Tripp’s career in the pharmaceutical industry spans more than 25 years and three continents. His diverse roles in pharma have included responsibilities for research and development, manufacturing (including quality assurance and quality control), sales and sales management, marketing management at both the domestic and international levels, as well as strategic planning and portfolio management. His business development activities have included acquisitions, mergers, divestitures and licensing, as well as the negotiation of co-development and co-selling agreements.
Prior to joining Labopharm, he was Senior Vice-President, Operations with Allelix Biopharmaceuticals (now NPS Allelix) and also President and CEO of its subsidiary, Allelix Neuroscience. Before that, he was Vice-President, Business Development for Wyeth-Ayerst Canada, with responsibility for licensing and acquisitions, new product development and health economics. He has also held positions with Miles Laboratories (now Bayer), Roussel Uclaf (now sanofi-aventis) and G.D. Searle (now Pfizer).
Mr. Howard-Tripp is a Member of Labopharm's Board of Directors and he also sits on the board of GeneNews Limited. He is a founding member and originating Chairman of the Canadian Healthcare Licensing Association and has been Chairman of several pharmaceutical industry committees. | 